Supraspinatus tendinopathy specialists in the UKSupraspinatus tendinopathy is degenerative, not inflammatory; anti-inflammatory treatment cannot address this, so management begins with physiotherapy-guided progressive loading to restore tendon capacity.Supraspinatus tendinopathy is degenerative, not inflammatory; anti-inflammatory treatment cannot address this, so management begins with physiotherapy-guided progressive loading to restore tendon capacity.
Single-stage vs two-stage ACI for cartilage repairTraditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.Traditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.
Which specialist to see for shoulder impingement painShoulder impingement is degenerative tendon wear, not acute inflammation, which explains why anti-inflammatory drugs fail and recovery takes months, not weeks.Shoulder impingement is degenerative tendon wear, not acute inflammation, which explains why anti-inflammatory drugs fail and recovery takes months, not weeks.
Choosing a ChondroFiller injection providerChondroFiller's collagen scaffold gels within minutes; accurate positioning demands real-time ultrasound guidance, and candidacy assessment requires pre-treatment MRI review.ChondroFiller's collagen scaffold gels within minutes; accurate positioning demands real-time ultrasound guidance, and candidacy assessment requires pre-treatment MRI review.
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
When knee cartilage repair is worth consideringCartilage lacks a blood supply and cannot self-heal, but surgical or minimally invasive repair can restore focal defects in otherwise healthy joints, potentially delaying knee replacement by years or decades.Cartilage lacks a blood supply and cannot self-heal, but surgical or minimally invasive repair can restore focal defects in otherwise healthy joints, potentially delaying knee replacement by years or decades.
ChondroFiller for Shoulder Cartilage DefectsFocal shoulder cartilage defects are now treatable with a single ultrasound-guided collagen injection that recruits the body's own repair cells, forming hyaline-like tissue over 12 months without surgery or general anaesthetic.Focal shoulder cartilage defects are now treatable with a single ultrasound-guided collagen injection that recruits the body's own repair cells, forming hyaline-like tissue over 12 months without surgery or general anaesthetic.
The cost of leaving a knee cartilage defect untreatedKnee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.Knee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.
Recovery after a ChondroFiller injectionChondroFiller works by recruiting the body's progenitor cells into a collagen scaffold to regenerate cartilage; improvement takes six to twelve weeks, not days.ChondroFiller works by recruiting the body's progenitor cells into a collagen scaffold to regenerate cartilage; improvement takes six to twelve weeks, not days.
What ChondroFiller's CE approval means for UK patientsChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
AMIC vs MACI for knee cartilage repairStandalone microfracture for knee cartilage defects has less than 60% survivorship at three years; AMIC adds a collagen membrane to stabilize repair, whilst MACI uses cultured chondrocytes and shows superiority in the SUMMIT trial for lesions over 3 cm².Standalone microfracture for knee cartilage defects has less than 60% survivorship at three years; AMIC adds a collagen membrane to stabilize repair, whilst MACI uses cultured chondrocytes and shows superiority in the SUMMIT trial for lesions over 3 cm².
What the ChondroFiller evidence actually showsChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.